Astrana Health, Inc.

Astrana Health, Inc. (ASTH) Market Cap

Astrana Health, Inc. has a market capitalization of $1.58B.

Financials based on reported quarter end 2025-12-31

Price: $31.50

0.90 (2.94%)

Market Cap: 1.58B

NASDAQ · time unavailable

CEO: Brandon K. Sim

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 2009-03-11

Website: https://www.astranahealth.com

Astrana Health, Inc. (ASTH) - Company Information

Market Cap: 1.58B · Sector: Healthcare

Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians and extenders, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was incorporated in 1985 and is headquartered in Alhambra, California.

Analyst Sentiment

79%
Strong Buy

Based on 11 ratings

Analyst 1Y Forecast: $34.20

Average target (based on 2 sources)

Consensus Price Target

Low

$26

Median

$37

High

$40

Average

$34

Potential Upside: 8.6%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 ASTRANA HEALTH INC (ASTH) — Investment Overview

🧩 Business Model Overview

Astrana Health Inc (NASDAQ: ASTH) is a healthcare solutions company operating at the nexus of value-based care, managed services, and coordinated healthcare delivery. The company integrates physician networks, technology platforms, and care management protocols to support healthcare providers and payers as they transition from fee-for-service models to risk-bearing, value-oriented arrangements. Astrana Health’s focus is on delivering enhanced outcomes, increased efficiency, and cost-containment for both providers and payers by optimizing healthcare administration and clinical management, primarily in secondary and primary care settings. The company’s business model involves partnering with independent physician associations (IPAs), medical groups, health systems, and payers, enabling them to leverage Astrana Health’s infrastructure and expertise in population health management, care coordination, and regulatory compliance. By acting as a conduit between providers and payers, Astrana Health aligns financial incentives across the healthcare continuum, helping to reduce unnecessary utilization and drive quality improvement measures.

💰 Revenue Streams & Monetisation Model

Astrana Health’s core revenues are derived through a diversified monetization approach centered around long-term contracts with provider groups and payers. Key revenue streams include: - **Capitation and Shared Savings:** The company receives per-member, per-month (PMPM) capitation fees from payers or downstream providers in exchange for managing healthcare costs. When medical costs are contained below budgeted thresholds, Astrana Health participates in shared savings arrangements, further aligning incentives around value-based outcomes. - **Administrative and Management Fees:** Astrana Health charges fees to physician organizations for back-office, compliance, and administrative services, including credentialing, billing, IT, and regulatory support. - **Care Coordination Fees:** Compensation for implementation and management of care coordination programs, chronic care management, and quality improvement initiatives, often structured on a fee-for-service or performance-bonus basis. - **Technology Solutions:** The company develops and licenses proprietary technology platforms to help clients manage population health, referrals, and utilization metrics. This blended monetization framework provides both predictable recurring revenues—via contract-driven payments—and upside potential through performance-linked incentives.

🧠 Competitive Advantages & Market Positioning

Astrana Health operates in a highly fragmented and evolving healthcare management market, where scale, technology, and track record are crucial differentiators. The company’s main competitive advantages include: - **Integrated Technology Platform:** Astrana Health leverages a proprietary suite of data analytics, workflow automation, and communication tools, providing actionable insights to drive down costs and enhance care outcomes. - **Deep Provider Relationships:** Extensive partnerships with physician groups, combined with a reputation for compliance and reliability, foster long-term, sticky client engagements. - **Scalable Infrastructure:** The company’s assets—care coordination teams, IT infrastructure, and regulatory expertise—enable expansion across new geographies and provider types without significant incremental investment. - **Regulatory and Risk Management Expertise:** Astrana Health possesses domain expertise in navigating complex, shifting regulatory frameworks related to Medicare Advantage, Medicaid, and commercial risk-sharing contracts. Overall, Astrana Health positions itself as a “one-stop” partner for providers and payers seeking efficiency and risk mitigation in the shift toward value-based care.

🚀 Multi-Year Growth Drivers

Multiple structural and strategic levers are poised to support Astrana Health’s long-term growth trajectory: - **Expansion of Value-Based Care Models:** The healthcare sector is experiencing a secular shift away from traditional fee-for-service toward value-based arrangements, with provider and payer clients seeking partners to manage risk and drive outcomes. - **Aging Population & Chronic Disease Prevalence:** Demographic trends, including a rising cohort of seniors enrolled in Medicare Advantage and increased rates of chronic illness, are expanding the addressable market for coordinated care services. - **Geographic Expansion:** Astrana Health has a scalable model that allows entrance into new states and metro areas where population health management adoption remains early-stage. - **Cross-Selling and Upselling:** Integration of technology solutions and care management services provides opportunities to deepen wallet share with existing customers. - **Strategic Acquisitions:** The highly fragmented landscape offers scope for disciplined M&A, giving Astrana Health access to new geographies, provider networks, and additional service capabilities.

⚠ Risk Factors to Monitor

Investors should monitor several key risk factors associated with Astrana Health’s business model: - **Regulatory and Policy Changes:** Changes to Medicare, Medicaid, or ACA reimbursement models can create profit volatility or impact contract terms with providers and payers. - **Integration and Execution Risk:** Expansion through M&A or onboarding of large provider groups entails execution risk, including the integration of IT systems and corporate cultures. - **Client Concentration:** Overreliance on a small number of payers or provider groups could heighten operational risk should contract terms change or relationships dissolve. - **Margin Pressures:** Competitive pricing dynamics, escalating compliance costs, or higher-than-expected medical loss ratios could erode profitability. - **Technology Disruption:** The evolution of healthcare IT and analytics requires continuous investment to maintain best-in-class capabilities and defend against emerging entrants.

📊 Valuation & Market View

Astrana Health is typically valued on the basis of revenue and EBITDA multiples, relative to both pure-play healthcare management peers and broader health IT comparables. The company’s recurring revenue model, high client retention, and alignment with secular value-based care trends support premium valuation multiples. Key metrics watched by market participants include organic revenue growth, EBITDA margin expansion, membership (covered lives), and medical cost management effectiveness. Investors also assess the pipeline for new partnerships and the pace of geographic or product expansion. Market sentiment remains tethered to the trajectory of value-based care adoption, the stability of regulatory frameworks, and the company’s ability to meaningfully scale while delivering consistent cost savings for clients.

🔍 Investment Takeaway

Astrana Health Inc offers differentiated exposure to the transformation of U.S. healthcare toward value-based, risk-managed care delivery. The company’s integrated technology platform, depth of provider relationships, and scalable infrastructure position it advantageously within a fragmented market undergoing significant structural change. Secular growth drivers—an aging population, rising prevalence of chronic conditions, and payer/provider demand for efficiency—align well with Astrana Health’s core capabilities and growth strategy. Major risks center on regulatory shifts, execution challenges, and industry competition, but these are partially mitigated by diversified revenue streams, long-term contracts, and continual investment in technology. For investors seeking access to healthcare services companies positioned at the intersection of technology and value-based care delivery, Astrana Health offers a compelling, long-duration growth thesis underpinned by favorable demographic and policy trends.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"ASTH reported revenue of $950.53M and a net income of $5.99M for the fiscal year ending December 31, 2025. The company's total assets stand at $2.22B, while total liabilities are $1.66B, resulting in total equity of $558.33M. ASTH has faced challenges in cash flow, with an operating cash flow of -$2.89M and a free cash flow of -$2.88M, suggesting liquidity issues. The firm's debt position is concerning with a net debt of $648.66M. Despite a strong top-line figure, its year-to-date performance shows a decline of 4.76% and a significant 1-year change of -24.68%. There are no dividends paid, indicating a focus on reinvestment or cash constraints. Analysts have a price target consensus of $32.75, implying potential upside from the current price of $24.02, but the declining market performance raises concerns about future growth and profitability."

Revenue Growth

Neutral

Strong revenue figures but stagnant growth observed.

Profitability

Caution

Positive net income, but overall profitability challenges due to cash flow issues.

Cash Flow Quality

Neutral

Negative operating and free cash flow indicate liquidity concerns.

Leverage & Balance Sheet

Neutral

Significant net debt to total equity ratio highlights potential financial risk.

Shareholder Returns

Neutral

Declining stock price and no dividends do not favor returns.

Analyst Sentiment & Valuation

Fair

Mixed analyst sentiment with a significant price target upside.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management delivered strong reported fundamentals (FY25 revenue $3.2B, adjusted EBITDA $205.4M, FCF $104.5M), highlighting margin leverage via automation (e.g., >2/3 of prior authorizations automatically approved) and disciplined delegated risk progression. However, the Q&A pressure surfaced that FY26 guidance depends heavily on Medicaid/exchange dynamics and conservative planning: a just-over-5% medical cost trend, ~1.0%–1.5% Medicaid rate/acuity negative spread, and 10%–15% Medicaid disenrollment assumptions were tied to roughly a -$20M Medicaid impact, plus mid-single-digit effects from exchange enrollment/mix and assuming $0 HQAF. On Medicare Advantage 2027, management pushed back on industry CMS headwinds (1.53% and 3.32%) and staked a view that Astrana rates should improve 2.5%–3%, potentially keeping 2027 margin-flat to only slightly dilutive. Overall tone was confident, but the analyst scrutiny translated into quantification of downside stacking and policy-driven enrollment risk that could widen the EBITDA range.

AI IconGrowth Catalysts

  • Medicare Advantage enrollment mid-single-digit growth (annual enrollment period)
  • Measured shift into full-risk structures: expects ~80% of revenue and >36% of owned membership in full-risk arrangements by end of Q1 2026
  • Continued clinical engagement: annual wellness visit completion approaching 80% in legacy Astrana markets; meaningful gains in Prospect populations
  • Automation/AI operational leverage: >2/3 of prior authorizations automatically approved

Business Development

  • Launched fully delegated partnership with a large payer partner in Texas on January 1, expanding delegated Medicare Advantage footprint with limited incremental overhead
  • Prospect Health acquisition closed; integration milestones include financial reporting standardization, live visibility into medical economics/utilization, and clinical workflow alignment under Astrana model
  • Successful onboarding/integration of a new care enablement client and its affiliated hospital at beginning of the year

AI IconFinancial Highlights

  • Q4 2025 revenue: $950.5M (+43% YoY); adjusted EBITDA: $52.5M (+50% YoY)
  • FY 2025 revenue: $3.2B (+56% YoY; high end of guidance); adjusted EBITDA: $205.4M (+21% YoY)
  • FY 2025 free cash flow: $104.5M; >50% conversion vs adjusted EBITDA (exceeded high end of prior conversion range)
  • Q4 net income attributable: $6M; EPS $0.12 vs -$0.15 prior year; adjusted EPS: $0.54
  • G&A as % of revenue: 6.8% in 2025, down 75 bps YoY (down 110 bps adjusted basis), despite $26M one-time transaction-related costs

AI IconCapital Funding

  • Ended Q4 with $429.5M cash and $648.7M net debt
  • Pro forma net leverage ratio: 2.6x
  • Q4 share repurchase: 634,000 shares at avg price $22.23
  • Board increased repurchase authorization cap from $50M to $100M; company may continue repurchases after filing 10-Ks

AI IconStrategy & Ops

  • Prospect integration: completed standardization of financial reporting across combined organization; established live visibility into medical economics/utilization trends; aligned clinical workflows/organizational structure under Astrana care model
  • Provider engagement/retention: >97% gross retention among Prospect PCPs over six months post-close
  • Clinical quality/commercial metrics: 24% higher gap-closure rate and 30% higher annual wellness visit completion rate vs less-engaged providers
  • Delegated care economics: run-rate profitability achieved in Southern Nevada in 2025; 20% YoY improvement in medical loss ratio
  • Material weakness: Form 12b-25 due to internal controls material weakness related to acquisition/purchase accounting timing/documentation; expects to file 10-Ks within the 15-day extension period

AI IconMarket Outlook

  • FY 2026 guidance: revenue $3.8B to $4.1B; adjusted EBITDA $250M to $280M; free cash flow $105M to $132.5M
  • Q1 2026 guidance: revenue $900M to $1.0B; adjusted EBITDA $60M to $70M
  • 2027 Medicare Advantage Advance Rate Notice commentary: expects Astrana impact to be more favorable than industry; expects rates positive 2.5% to 3% for Astrana (as of current assumptions)

AI IconRisks & Headwinds

  • 2026 cost trend embedded: conservatively just over 5% (vs mid-4% range in 2025); expects trend to remain mid-single-digit but higher than 2025 due to potential Medicaid/exchange disenrollments and adverse selection
  • Medicaid headwind in 2026 guide: ~1.0% to 1.5% negative Medicaid rate/acuity spread; assumes 10% to 15% Medicaid disenrollments throughout the year (quantified as roughly -$20M impact)
  • Exchange enrollment/mix headwind: mid-single-digit impact mentioned (offset not fully quantified) vs improved Medicare Advantage rates tailwind
  • California Hospital Quality Assurance Fund (HQAF): assumes $0 contribution (mid-single-digit impact)
  • EBITDA guide variability: stated as a 'stacked downside case' at the low end where negatives occur simultaneously
  • Regulatory/risk model environment: CMS estimated industry headwinds for 2027 advance notice—1.53% disallowed diagnosis sources headwind and 3.32% risk model revision/renormalization headwind (Astrana expects materially less impact due to model differences and conservative underwriting)
  • Potential expansion-market cohort losses and new market entry costs embedded in 2026 guidance

Sentiment: MIXED

Note: This summary was synthesized by AI from the ASTH Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (ASTH)

© 2026 Stock Market Info — Astrana Health, Inc. (ASTH) Financial Profile